All experts in the field of regenerative medicine and stem cell research are situated on one location at the Utrecht Science Park, in the Regenerative Medicine Center Utrecht (RMCU). Regenerative medicine is a promising field of interest, where scientists do research with the aim to restore the structure and function of damaged tissue and organs.
This week, Annetje Ottow (Vice President of UU’s Executive Board), Tineke Zweed (Executive Boards HU), Jan Henk van der Velden (Stichting Utrecht Science Park) and Fiona van ‘t Hullenaar (Director Real Estate and Campus) took the initiative of planting a tree next to the Bolognalaan cycling path.
Dutch biotechnology company Micreos announced it has secured €30 million in funding to accelerate the development of its endolysin technology, set to replace antibiotics. Proceeds are earmarked for the clinical development program of its endolysin XZ.700 and the USA launch of its breakthrough OTC Gladskin product for eczema.
Utrecht Science Park is the largest science park in the Netherlands. Together we are working on innovative solutions for societal issues such as a longer, healthier life and sustainability. A good example is the collaboration in the Utrecht Exposome Hub.
Synerkine Pharma B.V., which develops fusion proteins for the treatment of chronic pain, announced today that it successfully closed a EUR 3.3 million Series A financing from Thuja Capital, an undisclosed private investor, and the company’s founders.
Utrecht Science Park is the beating heart of Europe's most competitive region. We bring competence from business, industry and academia together in order to design and create healthier, safer and more sustainable cities for today and for subsequent generations.
Utrecht Science Park provides a vibrant, dynamic and exciting place to work, to study and to interact